Literature DB >> 27373395

Patient-reported outcomes 5 years after laser in situ keratomileusis.

Steven C Schallhorn1, Jan A Venter2, David Teenan2, Stephen J Hannan2, Keith A Hettinger2, Martina Pelouskova2, Julie M Schallhorn2.   

Abstract

PURPOSE: To assess vision-related, quality-of-life outcomes 5 years after laser in situ keratomileusis (LASIK) and determine factors predictive of patient satisfaction.
SETTING: Optical Express, Glasgow, Scotland.
DESIGN: Retrospective case series.
METHODS: Data from patients who had attended a clinical examination 5 years after LASIK were analyzed. All treatments were performed using the Visx Star S4 IR excimer laser. Patient-reported satisfaction, the effect of eyesight on various activities, visual phenomena, and ocular discomfort were evaluated 5 years postoperatively. Multivariate regression analysis was performed to determine factors affecting patient satisfaction.
RESULTS: The study comprised 2530 patients (4937 eyes) who had LASIK. The mean age at the time of surgery was 42.4 years ± 12.5 (SD), and the preoperative manifest spherical equivalent ranged from -11.0 diopters (D) to +4.88 D. Five years postoperatively, 79.3% of eyes were within ±0.50 D of emmetropia and 77.7% of eyes achieved monocular uncorrected distance visual acuity (UDVA) and 90.6% of eyes achieved binocular UDVA of 20/20 or better. Of the patients, 91.0% said they were satisfied with their vision and 94.9% did not wear distance correction. Less than 2.0% of patients noticed visual phenomena, even with spectacle correction. Major predictors of patient satisfaction 5 years postoperatively were postoperative binocular UDVA (37.6% variance explained by regression model), visual phenomena (relative contribution of 15.0%), preoperative and postoperative sphere and their interactions (11.6%), and eyesight-related difficulties with various activities such as night driving, outdoor activities, and reading (10.2%).
CONCLUSION: Patient-reported quality-of-life and satisfaction rates remained high 5 years after LASIK. Uncorrected vision was the strongest predictor of satisfaction. FINANCIAL DISCLOSURE: Dr. S.C. Schallhorn is a consultant to Abbott Medical Optics, Inc., Zeiss Meditec AG, and Autofocus Inc. and a global medical director for Optical Express. No other author has a financial or proprietary interest in any material or method mentioned.
Copyright © 2016 ASCRS and ESCRS. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27373395     DOI: 10.1016/j.jcrs.2016.03.032

Source DB:  PubMed          Journal:  J Cataract Refract Surg        ISSN: 0886-3350            Impact factor:   3.351


  5 in total

1.  Safety, efficacy and refractive outcomes of LASIK surgery in patients aged 65 or older.

Authors:  Paloma López-Montemayor; Jorge E Valdez-García; Denise Loya-García; Julio C Hernandez-Camarena
Journal:  Int Ophthalmol       Date:  2017-06-23       Impact factor: 2.031

2.  Effect of Postoperative Ocular Residual Astigmatism (ORA) on Treatment Outcome After Myopic Laser in situ Keratomileusis (LASIK).

Authors:  Johanna Nöthel; Toam Katz; Vasyl Druchkiv; Andreas Frings
Journal:  Clin Ophthalmol       Date:  2022-06-23

3.  A Comprehensive Investigation of Contrast Sensitivity and Disk Halo in High Myopia Treated With SMILE and EVO Implantable Collamer Lens Implantation.

Authors:  Wuxiao Zhao; Jing Zhao; Tian Han; Jifang Wang; Zhe Zhang; Xingtao Zhou
Journal:  Transl Vis Sci Technol       Date:  2022-04-01       Impact factor: 3.048

4.  Ocular Pain Symptoms in Individuals With and Without a History of Refractive Surgery: Results From a Cross-Sectional Survey.

Authors:  Brandon S Baksh; Melina Morkin; Elizabeth Felix; Carol L Karp; Anat Galor
Journal:  Cornea       Date:  2022-01-01       Impact factor: 3.152

5.  Patients' satisfaction and subjective happiness after refractive surgery for myopia.

Authors:  Shinichiro Matsuguma; Kazuno Negishi; Motoko Kawashima; Ikuko Toda; Masahiko Ayaki; Kazuo Tsubota
Journal:  Patient Prefer Adherence       Date:  2018-09-25       Impact factor: 2.711

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.